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Abstract
Purpose Intestinal subepithelial myofibroblasts (ISEMFs)1
are the predominant source of matrix metalloproteinase-2
(MMP-2) in gut, and a decrease in glutathione/oxidized
glutathione (GSH/GSSG) ratio, intracellular redox state in-
dex, occurs in the ISEMFs of patients with Crohn’s disease
(CD). The aim of this study is to demonstrate a relationship
between MMP-2 secretion and activation and changes of
GSH/GSSG ratio in ISEMFs stimulated or not with tumor
necrosis factor alpha (TNFα).
Methods ISEMFs were isolated from ill and healthy colon
mucosa of patients with active CD. Buthionine sulfoximine,
GSH synthesis inhibitor, and N-acetylcysteine (NAC), pre-
cursor of GSH synthesis, were used to modulate GSH/
GSSG ratio. GSH and GSSG were measured by HPLC
and MMP-2 by ELISA Kit.
Results In cells, stimulated or not with TNFα, a significant
increase in MMP-2 secretion and activation, related to in-
creased oxidative stress, due to low GSH/GSSG ratio, was
detected. NAC treatment, increasing this ratio, reduced
MMP-2 secretion and exhibited a direct effect on the secret-
ed MMP-2 activity. In NAC-treated and TNFα-stimulated
ISEMFs of CD patients’ MMP-2 activity were restored to
physiological value. The involvement of c-Jun N-terminal
kinase pathway on redox regulation of MMP-2 secretion has
been demonstrated.
Conclusion For the first time, in CD patient ISEMFs, a
redox regulation of MMP-2 secretion and activation related
to GSH/GSSG ratio and inflammatory state have been dem-
onstrated. This study suggests that compounds able to main-
tain GSH/GSSG ratio to physiological values can be useful
to restore normal MMP-2 levels reducing in CD patient
intestine the dysfunction of epithelial barrier.
Keywords Total andactiveMMP-2 .Crohn’sdisease .GSH/
GSSG ratio . N-acetylcysteine . Oxidative state
Introduction
Intestinal subepithelial myofibroblasts (ISEMFs) play an
important role in different functions in the normal and
pathological intestine being involved in tissue growth and
repair, tumourigenesis, inflammation and fibrosis [1]. The
intestinal location of ISEMFs, subjacent to the basement
membrane juxtaposed to the basal surface of epithelial cells,
is crucial for their involvement in the regulation of many
functions of epithelial cells, including epithelial cell prolif-
eration and differentiation, mucosal protection and wound
healing [2]. ISEMFs contribute in the epithelium repair
processes by synthesizing, in response to stimuli, growth
factors, such as transforming growth factor, epidermal
growth factor, proinflammatory cytokines, components of
extracellular matrix (ECM) and enzymes responsible of
ECM degradation [1, 3]. Matrix metalloproteinases
(MMPs), a family of Zn2+-containing neutral proteinases,
are secreted as inactive zymogens and are activated in the
extracellular space in order to cleave their substrates. Given
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that these enzymes are involved in the turnover and degra-
dation of ECM, they play an important role in the normal
tissue remodelling and in the modulation of matrix function
[4]. Nevertheless, it has been demonstrated that MMPs act
on substrates different from ECM proteins, regulate many
physiological functions, such cell proliferation, adhesion,
migration, growth factor bioavailability, chemotaxis and
signalling. The activity of MMPs is tightly controlled. In
fact, their latent form is activated, owing to the break of the
interaction between the residue cysteine and the zinc ion
present in the catalytic site. MMPs are also regulated at
transcriptional level by interleukins, growth factors and
proinflammatory mediators, such as tumour necrosis factor
alpha (TNFα) [5]. Activated MMPs are inhibited by tissue
inhibitors of metalloproteinases (TIMPs) which, by interact-
ing with the catalytic site of MMPs, prevent their binding to
substrates [5, 6]. MMPs play a crucial role also in patho-
logical conditions such as atherosclerotic lesion develop-
ment, inflammation, arthritis, tumour progression and
diabetes [6, 7]. In an inflammatory state, such as in inflam-
matory bowel diseases (IBD), MMPs play the important role
in controlling the function and migration of immune cells,
chemokine activity, matrix deposition and degradation [8].
Nevertheless, a dysregulated expression of MMPs may con-
tribute to intestinal tissue injury and inflammatory status in
IBD [9], characterized by an imbalance between pro- and
anti-inflammatory cytokines [10] and between synthesis and
degradation of ECM components [11]. In fact, increased
levels of MMPs found in inflamed tissue of IBD can be
responsible of the ulceration and fistula formation [11]; on
the contrary, an increased level of TIMP-1 protein is related
to fibrotic structures restore [12]. In particular, in Crohn’s
disease (CD), an increase in MMP production occurs, which
induces mucosal degradation, local leukocyte accumulation
into inflamed tissue and cytokineproduction [11].
MMP-9 and MMP-2 are the two known gelatinases that
degrade collagen; MMP-9 is produced principally by mac-
rophages and polymorphonuclear leukocytes, differently
from MMP-2 produced mainly by fibroblasts and other
connective tissue cells [13]. Both are up-regulated in in-
flamed intestine of IBD patients, and their increase is asso-
ciated with disease severity and activity [13, 14]. In
particular, high levels of MMP-2 may contribute to epithe-
lial barrier alteration that has a pivotal role in the pathogen-
esis of IBD (9).
ISEMFs are an important source of MMP-2; however, there
are few known regulation mechanisms of the production and
activity of this enzyme in ISEMFs of CD patients. Previously,
we have demonstrated in intestinal mucosa and ISEMFs isolat-
ed from ill and healthy colonic mucosa of CD patients the
presence of an increased oxidative state that was more remark-
able in ill mucosa and in ISEMFs isolated from ill colonic
mucosa of CD patients as compared to ISEMFs isolated from
healthy mucosa [15, 16]. It has been demonstrated that the
effect of oxidative stress on theMMP-2 expression, and activity
is cell-type dependent and tissue specific [17]. Considering
these previous data, the aim of this study was to demonstrate
a relationship between MMP-2 activity and secretion and
change in the glutathione/oxidized glutathione ratio (GSH/
GSSG ratio), in CD patient ISEMFs stimulated or not with
TNFα. Indeed, TNFα is a largely produced cytokine in CD
patients [18], and it is involved on MMP-2 regulation in serum
and intestine of these patients [19]. For this purpose, we have
determined total and active MMP-2 in ISEMFs, isolated from
mucosa of CD patients and control group, in which the intra-
cellular redox state was modulated through buthionine sulfox-
imine (BSO) or N-acetylcysteine (NAC), inhibitor and
precursor of glutathione (GSH) synthesis, respectively. The
results were also confirmed in CCD-18Co cells (18Co), a
myofibroblast cell line derived from human colonic mucosa
exhibiting many proprieties of ISEMFs [20].
Materials and methods
Patients
Surgical specimens were taken from macroscopically and
microscopically inflamed and unaffected colonic mucosa of
four patients affected by active CD (mean age, 33 years;
range, 20–55). The diagnosis of CD was ascertained accord-
ing to the usual clinical criteria [21], and the site and extent
of the disease were confirmed by endoscopic, histology and
enteroclysis. The primary site involved was ileocolonic in
all patients which were also in active phase of disease as
documented by the Crohn’s disease activity index (ranging
from 220–400). Patients with a score below 150 are consid-
ered to be in clinical remission, and scores above 450 reflect
severe CD [20]. Moreover, the patients were treated with
drugs prevalently used in CD pathology as mesalazine and
steroids, but none of them had been treated with anti-TNFα
therapies. Mucosal samples were also collected from colon-
ic areas of four patients undergoing colectomy for colon
cancer (mean age, 46 years; range, 36–60) used as control
group. Steroid treatment was suspended at least 1 month
earlier of surgery. All patients who participated in this study
were recruited after their informed consent.
Cell cultures, treatments and stimulations
Primary cultures of ISEMFs were isolated from healthy and ill
colonic mucosa of CD patients (HCD-ISEMFs and ICD-
ISEMFs, respectively) and from mucosa of control group (C-
ISEMFs) according the methods previously described by
Mahida [22] and were grown to at least passage 4 before they
were used in stimulation experiments. ISEMFs were
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characterized by immunocytochemical staining, as previously
described [23]. 18Co cells (normal human colon myofibro-
blasts) were obtained from American Type Culture Collection
(Manassas, VA, USA) and were used in our experiments with
population doubling level (PDL) 24–36 given that the line
begins to senesce at about PDL=42. All cells were cultured at
37 °C in a 5 % CO2 atmosphere in minimum essential medium
with 2 mM glutamine and 1.5 g/l sodium bicarbonate, 0.1 mM
non-essential amino acids, 1 mM sodium pyruvate and 10 %
foetal bovine serum. Culture media were supplemented with
72 mg/l penicillin and 100 mg/ml streptomycin.
ISEMFs were seeded in 12-well plates, serum starved at
confluence for 48 h and subsequently stimulated for 24 h with
1 ng/ml TNFα (Sigma), at the same concentration previously
used to stimulate these cells [16]. Forty eight-hour-starved C-
ISEMFs were also stimulated after 25 μM BSO treatment
performed during the last 16 h of starvation. Other stimulation
experiments were performed in all human ISEMF starved for
48 h in the presence or not of 20 mM NAC added during the
last 24 h. Each experiment performed on one cell line was
repeated in triplicate. Altogether, the colonic intestine cell
lines used were 12: four obtained from intestine of four con-
trols, eight from ill and healthy intestine of four CD patients.
18Co cells, seeded in 12-well plates, were serum starved at
confluence for 72 h and treated or not during the last 16 h or the
last 24 h with 25 μM BSO (named BSO) or 20 mM NAC
(named NAC), respectively. Other studies were performed in
48-h-starved cells treated during the last 16 h with 25 μMBSO
and to which 20 mM NAC was added for other 24 h after
removal or not of BSO; these cells were named NAC−BSO
andNAC+BSO, respectively. Subsequently, after these all treat-
ments, the cells were stimulated or not for other 24 h with 1 ng/
ml TNFα. BSO, NAC and TNFα concentrations are those used
previously to modulate intracellular redox state and which do
not reduce viability according to trypan blue exclusion test [16].
Additional experiments were performed in serum-starved
cells for 48 h in the presence or not of 25 μM BSO for the
last 16 h or 20 mM NAC for the last 24 h of starvation and
subsequently treated for 24 h with inhibitors of mitogen-
activated protein kinases (MAPKs) and in particular with
2 μM SB203580 (p38 MAPK inhibitor) or 5 μM UO126
(extracellular signal-regulated kinases (ERK1/2) inhibitor)
or 10 μM SP 600125 (c-Jun N-terminal kinase (JNK) (Cal-
biochem, La Jolla, CA, USA). These inhibitor concentra-
tions used are those that induced the maximum inhibition
without interfering with cellular viability.
GSH/GSSG ratio assay
GSH/GSSG ratio was obtained by cellular GSH and GSSG
levels measured in confluent ISEMFs and 18Co seeded in 6-
well plates, treated as reported above and collected in 0.2 ml
of 5 % (v/v) aqueous HClO4 plus 10 μl of 1 mM γ-glutamyl-
glutamate (internal standard). Cells were sonicated twice for
5 s, and GSH and GSSG were measured in cell extracts by
high-performance liquid chromatography (HPLC) methods as
previously reported [24].
MMP-2 activity assay
For quantification of active and total (pro and active) MMP-2,
the supernatants of ISEMFs and 18Co cells, the high-
sensitivity MMP-2 Activity Biotrak Assay System kit (GE
Healthcare) was used according manufacturer’s instructions.
This assay is performed in microtitre wells precoated with
anti-MMP-2 antibody that bound active MMP-2 able to acti-
vate a detection enzyme, which in turn activates a detectable
chromogenic substrate. Total MMP-2 activity (endogenously
active plus the proenzyme) is measured by the addition of α-
aminophenylmercuric acetate, which artificially activates the
inactive form ofMMP-2. Total and activeMMP-2 levels were
expressed in ISEMFs as fold increase over the total and active
MMP-2 levels measured in untreated and unstimulated C-
ISEMFs. Total and active MMP-2 levels were expressed in
18Co as fold increase over the total and active MMP-2 levels
measured in untreated and unstimulated 18Co.
SDS-PAGE zymography
The effect of thiol compounds on the activity of secreted
MMP-2 has been evaluated by gelatine zymography of
untreated 18Co medium. Aliquots of MMP-2 containing
medium of untreated and unstimulated 18Co cells under-
went electrophoresis on 8 % polyacrilamide gels containing
gelatine (1 mg/ml). Samples were mixed (10:1 v/v) with a
sample buffer consisting of 50 mM Tris–HCl pH6.8, 2 %
SDS, 20 % glycerol and 0.03 % bromophenol blue. After
electrophoresis, the gels were then soaked in 2.5 % Triton
X-100 (Sigma) on a shaker for 1 h at room temperature, then
cut in strips and incubated overnight at 37 °C in the activa-
tion buffer (50 mM Tris–HCl pH7.5, 5 mM CaCl2, 200 Mm
NaCl) at room temperature containing 20 mM NAC or
25 μM BSO. At the end of the incubation, the gels were
stained with Coomassie brilliant blue R-250 (Sigma
Aldrich, Italy) and distained with 30 % methanol and
10 % acetic acid. The gels were scanned by Chemo-Doc
(Bio-Rad), utilizing the Quantity One program (Bio-Rad).
Western blotting
Analysis of phosphorylation of JNK was performed in
ISEMFs and 18Co cells treated or not with BSO or NAC.
Cells were lysed in ice-cold lysate buffer (50mMTris/HCl pH
7.5, 1 % Triton X100, 150 mM NaCl, 100 mM NaF, 2 mM
EGTA, phosphatase and protease inhibitor cocktail, Sigma)
and, after 15 min on ice, were centrifuged at 11,600×g for
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10 min. Protein concentrations were determined by the bicin-
choninic acid solution protein reagent assay (Pierce) [25]
using bovine serum albumine as standard (Sigma). Equal
amounts of total proteins (20–25 mg) were loaded in each
line and were subjected to SDS/PAGE on 10 % (w/v) gel and
electrotransferred to PVDF membrane (GE Healtcare) that
was probed with specific antibody anti-JNK (cell signalling).
Subsequently, membranes were stripped by incubation for
30 min at 50 °C in buffer containing 62.5 mM Tris/HCl, pH
6.7, 100 nM 2-mercaptoethanol, 2 % SDS and, after extensive
washing, the membranes were reprobed with and anti-actin
(cell signalling) to normalize and to perform a densitometric
analysis. Secondary antibodies conjugated to horseradish per-
oxidase were used to detect antigen–antibody complexes with
a chemiluminescence reagent kit (GE Healthcare). Chemidoc-
Quantity-One software (Biorad Laboratories) was used to
perform quantitative analyses, and values of the bands were
expressed as percentage variations relative to values of unsti-
mulated and untreated cells.
Statistical analysis
All experiments were carried out three or more times. Data
are expressed as the mean±SEM, and statistical significance
of the differences was determined using Student’s t test. P≤
0.05 was considered statistically significant.
Ethical consideration
All patients who have participated in this study had to have
undergone an operation, and they were recruited after their
informed consent. We have required only this because the
surgeon should have anyhow resected the surgical samples
that we have used for our experiments.
Results
MMP-2 secretion and activation in ISEMFs
Figure 1a shows the data obtained by the analysis of MMP-2
secretion (total) and activation in the culture medium of
ISEMFs stimulated or not for 24 h with 1 ng/ml TNFα. A
significant enhanced secretion and activation of MMP-2 were
measured in untreated and not TNFα stimulated CD-ISEMFs
as compared to C-ISEMFs in the same conditions. Subse-
quently, TNFα stimulation induced a significant increase in
both MMP-2 production and activity in all the untreated cells,
and this effect was higher in CD-ISEMFs (Fig. 1a). Moreover,
the greatest increase was measured in ICD-ISEMFs stimulat-
ed or not with TNFα in comparison with HCD-ISEMFs.
To identify a relationship between the variations obtained
in MMP-2 secretion and activity and the different oxidative
status previously determined in ISEMFs [16], MMP-2 val-
ues were measured in ISEMFs, in which GSH levels and
GSH/GSSG ratio were modulated by treatment with 25 μM
Fig. 1 Total and active MMP-2 levels in ISEMFs treated or not with
BSO or NAC and stimulated or not with TNFα. Starved cells treated or
not with 25 μM BSO or 20 mM NAC, as reported in “Materials and
methods,” were stimulated or not for 24 h with 1 ng/ml TNFα. The
culture medium was collected and used to measure total and active
MMP-2 by immunoenzymatic method. a Total (T) and active (a)
MMP-2 in untreated and stimulated or not ISEMFs; b total MMP-2
in treated and stimulated or not ISEMFs; c active MMP-2 in treated
and stimulated or not ISEMFs. The data, expressed as fold increase
over the total and active MMP-2 values measured in untreated and
unstimulated C-ISEMFs, are the mean±SEM of four experiments
performed on four controls and four CD patients. Each experiment,
repeated in triplicate, was performed on a cell line obtained from one
control intestine or from ill or healthy intestine of one patient affected
by CD. Single asterisk (*) p≤0.05 compared to the unstimulated C-
ISEMFs. White-filled square (□) p≤0.05 compared to the respective
unstimulated ISEMFs. White-filled triangle (Δ) p≤0.05 compared to
the respective HCD-ISEMFs. Bullet (•) p≤0.05 compared to the re-
spective untreated C-ISEMFs.White-filled circle (○) p≤0.05 compared
to the respective untreated CD-ISEMFs
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BSO or 20 mM NAC [20]. Table 1 shows that GSH/GSSG
ratio decreased in BSO-treated C-ISEMFs, as compared to
untreated cells, and this value was similar to that detected in
CD-ISEMFs. On the contrary, NAC treatment increased
GSH/GSSG ratio in all the ISEMF groups, in comparison
with the respective untreated cells, and restored in HCD-
ISEMFs, the ratio to the values measured in C-ISEMF,
whereas this did not occur in ICD-ISEMFs (Table 1).
Figure 1b shows a significant increase in total MMP-2, as
compared to untreated cells, in BSO-treated C-ISEMFs,
stimulated or not with TNFα. On the contrary, NAC treat-
ment significantly reduced MMP-2 secretion in all ISEMFs
groups, stimulated or not with TNFα, as compared to the
respective untreated cells. In particular, in HCD-ISEMFs,
stimulated or not with TNFα, NAC treatment restored the
values of MMP-2 secretion to those detected in untreated C-
ISEMFs; whereas in ICD-ISEMFs, the total MMP-2
remained always higher than that measured in the same
condition in C-ISEMFs even if, in the presence of NAC, a
significant decrease, as compared to the respective untreated
cells, was registered. These data suggest a direct relationship
between the increase of total MMP-2 and that of intracellu-
lar oxidative state. This is evident considering the changes
of GSH/GSSG ratio obtained in the various experimental
conditions (Table 1). Moreover, MMP-2 activity increased
significantly in BSO-treated C-ISEMFs stimulated or not
with TNFα, as compared with the respective untreated C-
ISEMFs (Fig. 1c). NAC treatment decreased similarly
MMP-2 activity in all the ISEMF groups stimulated or not
with TNFα, differently to that observed for MMP-2 secre-
tion. The values of active MMP-2 in unstimulated and
NAC-treated ISEMFs were lower than those measured in
untreated and unstimulated C-ISEMFs. On the contrary, in
TNFα stimulated cells, MMP-2 activity was similar to that
measured in unstimulated and untreated C-ISEMFs.
MMP-2 secretion and activation in 18Co cells treated or not
with BSO or NAC
To validate the findings obtained in ISEMFs, the relation
between MMP-2 secretion and activation and GSH/GSSG
ratio was investigated also in 18Co cells treated or not with
BSO or NAC. As reported previously [12] in 18Co cells, BSO
decreased and NAC increased GSH/GSSG ratio (Fig. 2). This
ratio was restored to the value measured in untreated cells
when NAC was added to cells pretreated with BSO (NAC+
BSO) or after the removal of BSO (NAC−BSO) (Fig. 2).
Figure 3a, b shows that in BSO-treated 18Co cells stimulated
or not with TNFα, the total and active MMP-2 significantly
increased as compared to the respective untreated cells. The
total and active MMP-2 levels were significantly reduced in
NAC-treated 18Co cells, as compared to the respective un-
treated cells (Fig. 3a, b). In NAC+BSO- and NAC−BSO-
treated cells, stimulated or not with TNFα, MMP-2 secretion
was restored to the valuesmeasured in the respective untreated
cells (Fig. 3a) according to GSH/GSSG ratio (Fig. 2). On the
contrary, the activity of MMP-2 in NAC, NAC+BSO- and
NAC−BSO-treated 18Co cells, stimulated or not with TNFα,
was similarly lower than that detected in the respective un-
treated cells (Fig. 2b) independently of GSH/GSSG ratio
(Fig. 2). Moreover, the active MMP-2 values detected in
NAC-treated and TNFα-stimulated 18Co cells were very
similar to the values of unstimulated and untreated 18Co
(Fig. 3b). In order to determine whether the effects of NAC
and BSO were due to a direct interference with the activity of
secreted MMP-2, gelatin zymography of aliquots of untreated




– 9.00±0.75 6.70±0.40a 4.70±0.25a,c
NAC 23.4±1.75a 13.0±1.00b 7.00±0.35a,b
BSO 5.80±0.48a – –
Starved cells were treated with 25 μM BSO and/or 20 mM NAC as
reported in “Materials and methods,” and GSH/GSSG ratio was deter-
mined by GSH and GSSG values detected by HPLC method. The data
expressed as nmol/mg proteins are the mean±SEM of four experiments
performed, each in triplicate, on four controls and four CD patients.
Each experiment, repeated in triplicate, was performed on a cell line
obtained from one control intestine or from ill or healthy intestine of
one patient affected by CD
a p≤0.05 compared to the untreated C-ISEMFs
b p≤0.05 compared to the respective untreated cells
c p≤0.05 compared to HCD-ISEMFs
Fig. 2 Effect of NAC and BSO on the intracellular GSH/GSSG ratio
in 18Co cells. Starved cells were treated or not with 25 μMBSO and/or
20 mMNAC as reported in “Materials and methods.” GSH/GSSG ratio
values, obtained by GSH and GSSG levels measured by HPLC meth-
od, are the mean±SEM of six experiments repeated in triplicate. Single
asterisk (*) p≤0.01 compared to the untreated cells. Section symbol (§)
p≤0.05 compared to BSO treated cells
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was measured in gel cut in strips and incubated in the activa-
tion buffer containing 20 mM NAC or 25 μM BSO. Data,
reported in Table 2, indicate that BSO was ineffective, while
NAC reduced MMP-2 activity of about 70 %.
Role of MAPK inhibitors on total MMP-2 in 18Co cells
and ISEMF cells
Mitogen-activated protein kinases (MAPKs) are redox-
regulated proteins [26] involved in the inflammatory re-
sponse in colonic subepithelial myofibroblasts processes
[27] and in the cascades participating in MMPs activation
and expression [28–30]. Previously, we demonstrated that
GSH depletion by BSO-activated ERK1/2 and p38MAPK
increasing their phosphorylation in 18Co cells and in C-
ISEMFs and that an increased activation of MAPKs occurred
in HCD-ISEMFs and ICD-ISEMFs [16]. Therefore, we ex-
amined MMP-2 secretion in 18Co cells pre-incubated with
specific inhibitors of MAPKs, U0126 for ERK1/2 [31],
SB203580 for p38 MAPK [32] and SP600125 for JNK
[33]. Figure 4a shows that in untreated 18Co cells, only
SP600125 significantly decreased the MMP-2 secretion; on
the contrary, in BSO-treated cells, MMP-2 secretion was
inhibited by the three MAPKs inhibitors even if JNK in-
hibitor induced the major decrease in total MMP-2. No
inhibitor affected MMP-2 secretion in NAC-treated 18Co
cells (Fig. 4a). Moreover, similar values were measured in
untreated or BSO- or NAC-treated 18Co cells pre-
incubated with SP600125 and were very similar among
themselves (Fig. 4). Figure 4b shows that, in the three
groups of ISEMFs, MMP-2 secretion was significantly
inhibited only by SP600125.
Effect of BSO or NAC on the phosphorylation of JNK
in 18Co cells
To investigate the activation of JNK in conditions of the
different oxidative state, JNK phosphorylation in all ISEMF
group was detected. Figure 5a shows that the phosphorylation
of JNK increased significantly in CD-ISEMFs, as compared
to C-ISEMFs, and in ICD-ISEMFs, this phosphorylation was
higher than that measured in HCD-ISEMFs. An activation of
JNK phosphorylation in BSO-treated C-ISEMFs occurred
with respect to untreated C-ISEMFs. On the contrary, JNK
phosphorylation was reduced in all ISEMF groups treated
with NAC as compared to the respective untreated ISEMFs.
It is evident in Fig. 5a that NAC restored JNK phosphoryla-
tion to C-ISEMFs values only in HCD-ISEMFs in according
to GSH/GSSG ratio. These results have been also confirmed
in 18Co cells treated or not with BSO or NAC (Fig. 5b). The
phosphorylation of JNK increased significantly in BSO-
treated cells in comparison with the untreated ones and de-
creased in NAC-treated 18Co cells. However, in NAC+BSO-
and in NAC−BSO-treated cells, the phosphorylation levels
were restored to the values of untreated cells. Overall, these
results agree with the behaviour of total MMP-2 levels (Fig. 1)
and indicate that JNK phosphorylation is inversely related to
GSH/GSSG ratio (Table 1, Fig. 2).
Fig. 3 Total and active MMP-2 levels in 18Co cells treated or not with
BSO or NAC and stimulated or not with TNFα. Starved cells treated or
not with 25 μM BSO and/or 20 mM NAC, as reported in “Materials
and methods,” were stimulated or not for 24 h with 1 ng/ml TNFα. The
culture medium was collected and used for total (a) and active (b)
MMP-2 assay by immunoenzymatic method. The data, expressed as
fold increase of untreated and unstimulated cell values, indicated with
the arrow, are the mean±SEM of six experiments repeated in triplicate.
Single asterisk (*) p≤0.05 compared to the untreated and unstimulated
cells. White-filled triangle (Δ) p≤0.005 compared to the respective
BSO untreated and stimulated cells. Section symbol (§) p≤0.05 com-
pared to the untreated and stimulated cells
Table 2 Effect of BSO and NAC on the activity of secreted MMP-2
Treatment MMP-2 activity (% of control)
Control 100±11.3
NAC 20 mM 30±7.9a
BSO 25 μM 108±14
Aliquots of MMP-2 containing medium of untreated 18 Co were run
on polyacrilamide gels containing gelatine. Then, gels cut in strips
were incubated in the activation buffer in the presence or not (control)
of BSO or NAC as described in “Materials and methods.” Values are
the mean±ESM of three experiments
a p≤0.01 compared to control
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Discussion
Intestinal fibroblasts and ISEMFs are the predominant
source of MMP-2 in gut [34–36], and an increase in the
number of myofibroblasts in the intestine of CD patients
occurs [37]. These cells, secreting ECM and MMPs, are
involved in changes of tissue architecture in this pathology.
MMP-2 is commonly expressed by normal tissue participat-
ing in the control of collagen homeostasis in tissue [38, 39],
and MMP-2 staining in normal and inflamed colon is local-
ized in subepithelial and fibroblast/myofibroblast besides in
mononuclear macrophage-like cells [40]. Data reported in
literature show that activation and expression of MMP-2
increase in inflamed colonic mucosa if compared with
non-inflamed colonic mucosa from the same CD patients
[13, 14, 41] leading to epithelial damage, intestinal ulcera-
tion and/or fistula formation [14, 42, 43]. In fact, the in-
crease in MMP-2 is most pronounced in colonic mucosa
ulceration of IBD patients and in fistulae of CD patients [14,
40]. In this study, we showed that a significant increase in
total and active MMP-2 in CD-ISEMFs occurs, as compared
to C-ISEMFs. Moreover, in ICD-ISEMFs, these increases
are more remarkable than those measured in HCD-ISEMFs
in accordance with the increase in oxidative stress that
characterizes CD-ISEMFs and in particular ICD-ISEMFs
[16]. Therefore, we demonstrated, for the first time in these
cells, a relation between the up-regulation of MMP-2 secre-
tion and activation, stimulated or not by TNFα, and the
decrease in GSH/GSSG ratio measured in CD-ISEMFs.
The strong relationship between this ratio and MMP-2 se-
cretion was highlighted in ISEMFs and 18Co cells by mod-
ulating GSH/GSSG ratio through NAC and/or BSO
treatment. Moreover, it has been demonstrated in 18Co cells
Fig. 4 Effect of inhibitors of MAPKs inhibitors on total MMP-2 levels
in 18Co cells and ISEMFs; 2 μM SB 203580 or 5 μM U0126 or
10 μM SP600125 were added to starved 18Co cells, treated or not with
25 μM BSO or 20 mM NAC, as reported “Materials and methods,” (a)
and starved ISEMFs (b). Subsequently after 24 h, the culture medium
was collected and used for total MMP-2 assay by immunoenzymatic
method. The data, expressed as fold increase of untreated cell values,
indicated with the arrow, are the mean±SEM of six experiments
repeated in triplicate for 18Co cells and the mean±SEM of four experi-
ments performed on four controls and four CD patients. In ISEMFs,
each experiment, repeated in triplicate, was performed on a cell line
obtained from one control intestine or from ill or healthy intestine of
one patient affected by CD. Single asterisk (*) p≤0.005 compared to
the respective 18Co cells without inhibitors. White-filled circle (○) p≤
0.05 compared to the respective ISEMFs without inhibitors
Fig. 5 Effect of BSO or NAC on JNK phosphorylation in 18Co cells
and ISEMFs. Starved ISEMFs (a) or starved 18Co (b) were treated
with 20 mM NAC and/or 25 μM BSO, as reported in “Materials and
methods.” Western blot analysis of cell lysate with anti-phospho-JNK
and anti-β-actin antibodies was performed. p-JNK values normalized
with actin band were obtained by densitometric analysis of four sepa-
rate experiments performed on four controls and four CD patients (a)
or three separate experiments performed on 18Co cells (b). The values
are reported as the mean percentage of phosphorylation±SEM relative
to the values obtained in untreated C-ISEMFs or in untreated 18Co
cells (100 %). Single asterisk (*) p≤0.05 compared to the untreated C-
ISEMFs (a) or untreated 18 Co cells (b).White-filled circle (○) p≤0.05
compared to the untreated ICD-ISEMFs. White-filled triangle (Δ) p≤
0.05 compared to the untreated HCD-ISEMFs
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that NAC is able to remove BSO effect, restoring GSH/
GSSG ratio and MMP-2 value to those of untreated cells.
The dependence of the MMP-2 secretion from GSH/GSSG
ratio is particularly evident in ISEMFs stimulated or not
with TNFα and treated with NAC. In fact, in NAC-treated
HCD-ISEMFs, the total MMP-2 levels and GSH/GSSG
ratio are similar to those measured in untreated C-ISEMFs.
On the contrary, in NAC-treated ICD-ISEMFs, MMP-2
secretion is lower than that of untreated C-ISEMF, in agree-
ment with a higher value of GSH/GSSG ratio.
The increase inMMP-2 activity can be also related to GSH/
GSSG ratio decrease in CD-ISEMFs untreated and stimulated
or not with TNFα, as compared to the respective untreated C-
ISEMFs. This datum agrees with the activation induced by
oxidants on 72 KDa full-length MMP-2 through the disrup-
tion in the catalytic site of cysteine–Zn2+ interaction [4]. Other
data show also an induction of pro-MMP-2 activity due to S-
glutathiolation of the cysteine in the propeptide domain, relat-
ed to an increase of oxidative state [44]. Effectively, in BSO-
treated C-ISEMFs and 18Co cells, the decrease of GSH/
GSSG is related to the increase of MMP-2 activity.
Differently to what was observed for MMP-2 secretion,
NAC effect on MMP-2 activity in ISEMFs and 18Co cells is
not related to the changes in GSH/GSSG ratio but to a direct
effect of NAC on the proteinase, as demonstrated by gelatine
zymography. In fact, NAC reduces MMP-2 activity in
ISEMFs and 18Co equally and independently from GSH/
GSSG ratio. Moreover, NAC abolishes the stimulatory effect
of TNFα, restoring MMP-2 values in ISEMFs and 18Co cells
to those of unstimulated and untreated C-ISEMFs and 18Co,
respectively. The increased production of TNFα occurs dur-
ing inflammation in the colon, and this stimulates the MMP-2
secretion [35, 36]. Our results suggest that TNFα in CD can
amplify the inflammatory response also through the up-
regulation of MMP-2 secretion and activation in ISEMFs. In
fact, an increased MMP-2 activity may play a role in the
degradation of basement membrane which represents the sup-
port for endothelial and epithelial cells [40], increasing inva-
sion of inflammatory cells [45]. Moreover, in ISEMFs, MMP-
2 could be involved in the development of fibrosis, such as it
occurs in the hepatic fibrosis [46]. Therefore, for this, it should
be very important to maintain MMP-2 values at physiological
levels. Therefore, NAC, which reduces in ISEMFs MMP-2
secretion by the increase of GSH/GSSG ratio and suppresses
the activation of MMP-2 induced by TNFα, presents an
important dual role in the normalization of MMP-2 values.
MAPK pathways can be activated by oxidative stress,
and they play an important role in the regulation of MMP
expression [47–49]. Our data show that JNK is principally
involved in the secretion of MMP-2 both in ISEMFs and in
18Co cells, and JNK phosphorylation levels in both cell
types are related to GSH/GSSG ratio. However, in BSO-
treated 18Co cells, a low but significant reduction total
MMP-2 occurs also in the presence of ERK1/2 and p38
MAPK inhibitors showing a partial involvement of these
kinases on total MMP-2 levels. In fact, previously, we also
observed in BSO-treated 18Co cells an increase in ERK1/2
and p38 MAPK phosphorylation [16]. Differently to what
verified for ERK1/2 and p38 MAPK [16], NAC decreases
the JNK phosphorylation in 18Co cells and ISEMFs; this is
in accordance with the increase in GSH/GSSG ratio and the
decrease in total MMP-2. NAC restores in 18Co cells JNK
phosphorylation to the levels of untreated cells after and
during BSO treatment, as such as restores GSH/GSSG ratio
and total MMP-2. Differently to that occurs in HCD-
ISEMFs, NAC treatment in ICD-ISEMFs does not restore
JNK phosphorylation, GSH/GSSG ratio and MMP-2 levels
to values of C-ISEMFs confirming the relationship among
them. All together, these data show that NAC down-
regulation effect on MMP-2 secretion is comparable to that
observed with JNK inhibitor, suggesting that the increase of
GSH/GSSG ratio induced by NAC reduces MMP-2 secre-
tion inhibiting JNK. In fact, JNK can phosphorylate tran-
scription factors such as JunB, JunD, c-fos, ATF2 and
ATF3, which, along with c-Jun, make up the activator
protein-1 transcription factor (AP-1) [50]. AP-1 modulates
the expression of several stress-responsive genes and is an
element found in most MMP promoters [51].
Conclusions
Our finding in CD-ISEMFs demonstrates (1) a relationship
among MMP-2 secretion and activation, GSH/GSSG ratio
and inflammatory state; (2) the involvement of ISEMFs,
stimulated or not with TNFα, in the increased activity and
production of MMP-2 in intestinal mucosa of CD patients;
(3) that NAC induced down-regulation of MMP-2 secretion
through the increase of GSH/GSSG ratio, and this together
with a direct action of NAC on the enzyme contribute to
reduce MMP-2 activity; (4) that NAC may also suppress
MMP-2 activation induced by TNFα and restore MMP-2
activity to physiological levels; and (5) the involvement of
JNK pathway on redox regulation of MMP-2 secretion.
Moreover, this study suggests that compounds are able to
modulate GSH components and to maintain GSH/GSSG
ratio to physiological values can be useful to restore
MMP-2 activity to normal values acting only on MMP-2
secretion and not directly on its activity. Indeed, the restore
of normal MMP-2 level activity and/or expression can be
important for help reduce in intestine of CD patients the
dysfunction of epithelial barrier.
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